Fondazione Italiana Linfomi

What Fondazione Italiana Linfomi does

Fondazione Italiana Linfomi (FIL) is an Italian non-profit research foundation (Ente del Terzo Settore, formerly Onlus) established on October 1, 2010, with its legal headquarters in Alessandria and research offices in Modena. The foundation coordinates independent, non-pharmaceutical-funded clinical research on lymphomas across a network of more than 150 Italian research centers, offering a shared scientific, organizational, regulatory, and data-management framework for multicenter investigator-initiated trials. As of 2026 it has activated over 100 clinical studies and enrolled more than 10,000 patients since 2010, addressing what it describes as approximately 15,000 new lymphoma diagnoses per year in Italy, or roughly one new patient every two hours.

FIL's core service portfolio comprises multicenter clinical trial coordination, an MRD (Minimal Residual Disease) laboratory network, a developing Biobank, and a Clinical Trial Data Management System built around internally developed electronic Case Report Forms (CRFs) and statistical analysis infrastructure. It supplements this research base with educational programs including the annual Bando Giovani Ricercatori young-researcher grant, the Premio Brusamolino scholarship, FIL Training Courses, the annual Riunione Plenaria Nazionale, and the 'Young Side of Lymphoma' conference. Patient-facing services include support groups, educational materials, and resources on psychological, nutritional, fertility, legal, and financial aspects of living with lymphoma.

FIL is funded entirely through altruistic and institutional streams rather than commercial product sales: private donations (suggested at €25, €50, and €100 tiers, including in-memory and birthday donations), the Italian 5x1000 tax designation mechanism, corporate sponsorships and partnerships, legacy/charitable gifts, and targeted grants such as the €30,000 awarded by AIL in June 2026 for the FIL_CTCL study on Cutaneous T-cell Lymphomas. The foundation is governed by a Comitato Direttivo (Directing Committee), with Prof. Marco Ladetto serving as Scientific Director and Giuseppe Rossi as Direttore Operativo, and it maintains ISO 9001-aligned quality certification and GDPR compliance.

Name

Fondazione Italiana Linfomi

Legal name

Fondazione Italiana Linfomi ETS

Website

https://filinf.it

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Fondazione Italiana Linfomi is an Italian non-profit foundation established in 2010 that coordinates independent clinical research on lymphomas across more than 150 Italian research centers, supporting investigator-initiated trials, an MRD laboratory network, and patient and researcher programs funded by donations and grants.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090)

akta.pro industry

PRIMARYHLAGACAA

Site Network Operators & SMOs

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYBPAGACAA

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Business & Public Services/Nonprofit, NGO & Social Services/Health & Medical Nonprofits

SECONDARYHLAGACAE

Clinical Trial Site Operations & Study Coordination

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAGACAG

Clinical Trial Monitoring Support (On-site/Remote)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAGACAH

Decentralized & Hybrid Trial Site Services (Home Health/Nursing)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

Keywords

• Clinical lymphoma research
• Hematology research coordination
• Non-profit medical research
• Clinical trial management
• Medical research foundation

Headquarters

HQ city

Alessandria

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Private Donations: Individual donations received through the foundation's website, fixed amounts (25€, 50€, 100€), online donations, and in-memory donations. Primary funding source for research activities.
2. 5x1000 (Tax Designation): Italian tax mechanism allowing taxpayers to designate 0.5% of IRPEF tax to non-profit organizations and scientific research institutions.
3. Research Grants and Partnerships: Funding from organizations like AIL (30,000 euros for FIL_CTCL project) and potentially other institutional donors supporting specific research projects.
4. Legacy Giving and Charitable Gifts: Planned giving programs including wills, legacies, and solidary gifts that supporters can contribute to fund future research.
5. Corporate Partnerships: Sponsorships and partnerships with companies supporting lymphoma research through various fundraising initiatives and events.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Fondazione Italiana Linfomi is an Italian non-profit foundation (ETS) that coordinates independent clinical research on lymphomas across a national network of more than 150 hematology centers. It designs and runs multi-center clinical trials, operates centralized MRD laboratories, funds young investigator grants, delivers training courses, and supports patient advocacy activities for the lymphoma community in Italy.

Product overview

Fondazione Italiana Linfomi is a non-profit research foundation (ETS) that coordinates clinical research on lymphomas across Italy. The organization does not operate a unified software product platform but rather provides a portfolio of research support services, educational offerings, and patient support programs. The core service offering includes: clinical trial coordination and management across over 150 Italian centers, MRD (Minimal Residual Disease) laboratory services, researcher training and education programs, grant programs for young researchers, patient support groups, and scientific publications. The organization facilitates collaboration between hematology centers and researchers to improve lymphoma diagnosis, therapies, and patient quality of life.

Differentiator

Problem solved

Functional benefit

Products and services

• Multi-center lymphoma clinical trials coordination Design, sponsorship, and coordination of independent clinical trials in Hodgkin and non-Hodgkin lymphomas, delivered to Italian hematology centers and their patients through the foundation's national network.
• Centralized MRD (Minimal Residual Disease) laboratories Centralized molecular diagnostics and minimal residual disease testing services for lymphoma patients enrolled in foundation-sponsored trials and for participating hematology centers.
• Bando Giovani Ricercatori (Young Researchers Grant Program) Competitive grant funding for early-career Italian researchers conducting independent lymphoma research projects, supporting the foundation's mission to develop next-generation investigators.
• Training courses in hematology and lymphoma Educational courses and training programs for hematologists, researchers, and clinical staff participating in the foundation's network and trials.
• Gruppo Pazienti (Patient Advocacy Program) Patient support and advocacy activities for Italian lymphoma patients and their families, including information, peer support, and connection to clinical research opportunities.
• Riunioni Plenarie (Plenary Scientific Meetings) Periodic scientific plenary meetings bringing together the foundation's member centers to align on ongoing trials, results, and new research priorities in lymphoma.
• FIL Club membership community Membership-based community that connects Italian hematology professionals and supporters with the foundation's research, training, and networking activities.
• Premio Brusamolino scientific award Recognition award given by the foundation to researchers contributing to lymphoma research, supporting visibility and motivation in the field.

Quantifiable outcome

• Over 100 clinical studies activated to improve lymphoma diagnosis and treatment
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• AIL - Associazione Italiana contro Leucemie, Linfomi e MielomacoreStrategic or Co-development Partner · 18 June 2026FIL participated in AIL's national press conference for the Day Against Leukemias, Lymphomas and Myeloma. AIL provided 30,000 euros in funding for FIL_CTCL study on Cutaneous T-cell lymphomas. The two organizations share the objective of improving knowledge of hematological diseases and developing new treatment opportunities through independent clinical research.
• Lymphoma CoalitioncoreStrategic or Co-development PartnerInternational network providing support to lymphoma patients. FIL participates in the Lymphoma Patient Charter initiative, contributing to international efforts to improve patient care standards and ensure lymphoma patients' priorities are represented in international debate.
• SIE - Società Italiana di EmatologiacoreStrategic or Co-development PartnerItalian Hematology Society. FIL presented eight scientific contributions at the 52nd SIE National Congress 2025 in Milan, covering aspects from innovative therapies for refractory patients to strategies for improving quality of life for long-term survivors.
• SIES - Società Italiana di Ematologia SperimentaleminorStrategic or Co-development PartnerItalian Society of Experimental Hematology. Collaboration during national congresses and shared interest in lymphoma research.
• GITMO - Gruppo Italiano Trapianto Midollo OsseominorStrategic or Co-development PartnerItalian Group for Bone Marrow Transplantation. Collaboration on cellular therapy research including CAR-T treatments and infections in cellular therapies.
• GIMEMA - Gruppo Italiano Malattie EMatologiche dell'AdultominorStrategic or Co-development PartnerItalian Group for Adult Hematologic Diseases. Collaboration on quality of life research for lymphoma patients treated with CAR-T therapy.
• EHA - European Hematology AssociationcoreStrategic or Co-development PartnerEuropean Hematology Association. FIL participates in the LyG Cantera program and presents research at EHA annual congress. Collaboration on 'The Young Side of Lymphoma' educational initiative.
• ASCO - American Society of Clinical OncologycoreStrategic or Co-development PartnerFIL presents research at ASCO annual congress, contributing to international visibility of Italian lymphoma research.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• GITMO - Gruppo Italiano Trapianto Midollo Osseo: Italian non-profit research group focused on bone marrow transplantation and cellular therapies. Comparable operating model (national coordinator of multicenter studies, academic independence), with overlapping membership and explicit collaboration with FIL.
• GIMEMA - Gruppo Italiano Malattie EMatologiche dell'Adulto: Italian non-profit coordinating multicenter hematology clinical trials across Italy. Most direct peer to FIL — also operates a national investigator-initiated trial network with overlapping membership and shared studies (e.g., CAR-T quality of life research).
• German Lymphoma Study Group (GLSG): German academic lymphoma research consortium coordinating multicenter clinical trials. Comparable to FIL in mission, structure, and disease focus, but operating a different national network that FIL could complement in pan-European studies.
• LYSA - Lymphoma Study Association: French cooperative group dedicated to lymphoma clinical research, operating a national network of academic centers. Closest international analog to FIL — same disease focus, independent non-profit governance, and comparable investigator-initiated trial model.

Regional players

• Fondazione Italiana Sindromi Mielodisplastiche (FISM): Italian non-profit foundation for myelodysplastic syndromes research. Same non-profit research-foundation structure as FIL, with overlapping professional staff (e.g., Elisa Masiera previously worked at FISM), but focused on a different hematologic disease.

Emerging players

• Lymphoma Coalition: Global network of lymphoma patient organizations. FIL participates in the Lymphoma Patient Charter initiative; aligned mission around lymphoma patient advocacy and research, though operating globally rather than as a clinical trial coordinator.
• AIL - Associazione Italiana contro Leucemie, Linfomi e Mieloma: Italian patient advocacy and research-funding non-profit for hematologic malignancies. Both funder and strategic partner of FIL — provides research grants (€30K to FIL in 2026) and patient support infrastructure that overlap with FIL's mission.
• SIE - Società Italiana di Ematologia: Italian scientific society for hematology professionals. Hosts the national congress where FIL presents research; serves as an academic counterpart rather than a direct competitor, but coordinates overlapping scientific communities.

Broad incumbents

• European Hematology Association (EHA): European professional society for hematology. FIL participates in EHA's LyG Cantera program and presents at the EHA annual congress — a broader-incumbent scientific society that overlaps with FIL's research-dissemination and education agenda.
• The Leukemia & Lymphoma Society (LLS): Largest U.S. non-profit dedicated to blood cancer research, patient support, and advocacy. Comparable mission to FIL in lymphoma research funding and education, but operates at much larger scale and global reach rather than as a clinical trial site network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/FIL_ETS
• YouTubeyoutube.com/c/FondazioneItalianaLinfomiOnlus
• Facebookfacebook.com/FondazioneItalianaLinfomi
• LinkedInlinkedin.com/company/fil-fondazione-italiana-linfomi
• Instagraminstagram.com/fondazioneitalianalinfomi

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fondazione Italiana Linfomi